Form 4: Charles River Labs Director Sells Shares Under 10b5-1 Plan

Director James C. Foster of Charles River Laboratories International, Inc. reported a sale of 75,000 common shares, executed under a pre-established Rule 10b5-1 trading plan.

Summary

• Director James C. Foster sold 75,000 shares of common stock in Charles River Laboratories International, Inc. on June 29, 2026.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted by Mr. Foster on March 6, 2026.
• Following this transaction, Mr. Foster directly beneficially owns 31,596 shares of common stock.
• Additional holdings are reported indirectly through various trusts and held by a spouse, totaling 10,780 shares in a 2025 GRAT, 20,000 shares in a 2026 GRAT, 155,611 shares by Trust, 10,000 shares by Trust Held By Spouse, and 5,423 shares in a 2024 GRAT.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant share sale by a director, although it was executed under a pre-planned Rule 10b5-1 trading plan.

Negatives

• A significant number of shares (75,000) were sold by a director.

Future Outlook

No forward-looking statements or guidance are present in this filing.

Industry Context

StockSavvy.ai notes that insider sales, particularly under Rule 10b5-1 plans, are common for executives and directors to diversify holdings or manage personal finances. The significance of this sale depends on the director's overall holdings and the company's recent performance and outlook.

Stakeholder Impact

• Shareholders may view the sale of a large number of shares by a director with some concern, although the Rule 10b5-1 plan mitigates concerns about insider trading.
• The company's management team and board of directors are impacted by the reporting of insider transactions, which are subject to regulatory scrutiny.

Key Dates

Recommendation

The filing reports a significant sale of shares by a director under a Rule 10b5-1 plan. While this indicates a planned divestment rather than immediate negative news, a large sale by an insider warrants attention. Without further context on the company's performance or the director's rationale, a 'hold' recommendation is prudent, suggesting investors monitor future filings and company performance.

Keywords

Charles River Laboratories, CRL, Form 4, Insider Trading, Rule 10b5-1, Director Sale, Beneficial Ownership, Common Stock